Navigation

Multiple sclerosis (relapsing-remitting) - fingolimod [ID63]

Fingolimod for the treatment of relapsing-remitting multiple sclerosis

Status: History
Expected date of issue: April 2012
Referral date: November 2008
Process: STA
Topic area:
  • Central nervous system
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Fiona Rinaldi
Communications manager: Paul Cooney
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 18 March 2011
1st appraisal committee meeting: 06 July 2011
2nd appraisal committee meeting 05 October 2011
3rd appraisal committee meeting: 01 February 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Novartis (fingolimod)

Patient/carer groups

  • Multiple Sclerosis Trust
  • Multiple Sclerosis Society

Professional groups

  • Association of British Neurologists
  • Royal College of Nursing
  • Royal College of Physicians

Others

  • Department of Health
  • NHS North Yorkshire and York
  • NHS South Staffordshire
  • Welsh Assembly Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • Bayer (interferon beta-1b)
  • Biogen Idec (interferon beta-1a, natalizumab)
  • Merk Serono (interferon beta-1a)
  • Sanofi-Aventis (glatiramer acetate)
  • Teva (glatiramer actetate)

Relevant research groups

  • None

Evidence Review Group

  • National Institute for Health Research Health Technology Assessment Programme
  • NHS Centre for Reviews and Dissemination and Centre for Health Economics - York

Associated Guideline Groups

  • None

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
25 February 2011 Due to resource constraints and efficiency scheduling requirements for the current work programme, NICE has had to decide to re-schedule this appraisal. The date of the first Committee meeting has therefore changed.
30 July 2010 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin during mid September 2010. The deadline for submissions is expected in approximately mid November 2010.
24 January 2010 Due to resource constraints and efficiency scheduling requirements for the current work programme, NICE has had to decide to re-schedule the first Appraisal Committee meeting for a number of the technology appraisal topics.

In rescheduling these topics we have been careful to maintain our ability to issue timely recommendations.

The appraisal of Fingolimod for the treatment of relapsing-remitting multiple sclerosis is one of the topics that has been identified.

The first appraisal committee discussion will now take place on 06 July 2011.  The second committee meeting (if required) will also be rescheduled.
Top


 

Key documents

This page was last updated: 05 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.